Available at: (Accessed: October 2025) Data on the impact of finasteride on DED is, therefore, lacking, and robust clinical studies are required to better understand the potential link
Many patients notice improvement within 1-2 weeks, particularly reduced pain and improved mobility at injury sites
Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under FFS as of January 2026 (Figure 1)
Fast access to science-backed GLP-1 weight loss medications delivered to your doorstep no in-person visits, no insurance hassle
Community-reported (anecdotal): headache, brain fog or mental fatigue, irritability, anxiety, nausea or other GI upset, appetite and sleep changes, blood-pressure changes, and skin reactions with transdermal-DMSO use